Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.
Fotios Loupakis
Consultant or Advisory Role - Amgen; Bayer; Roche; Sanofi
Chiara Cremolini
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Gianluca Tomasello
No relevant relationships to disclose
Monica Ronzoni
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose
Chiara Valsuani
No relevant relationships to disclose
Silvana Chiara
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Francesca Negri
No relevant relationships to disclose
Carlo Barone
No relevant relationships to disclose
Stefano Vitello
No relevant relationships to disclose
Mauro D'Amico
No relevant relationships to disclose
Cristina Granetto
No relevant relationships to disclose
Gabriella Fontanini
No relevant relationships to disclose
Daniela Tomcikova
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose